Targeting YTHDF1 using CRISPR or VNPs-siYTHDF1 enhances the efficacy of anti-PD1 therapy in microsatellite instability—high (MSI-H) CRC and overcomes resistance in microsatellite-stable (MSS) CRC [71]. Here, YTHDF1 is linked to colorectal carcinoma.